Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001217 · ClinicalTrials.gov registry record · Phase 3

Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study

A Phase 3 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 3
Development phase
260
Enrollment target

NCT00001217: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).

NCT00001217 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 260 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001217, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 3
Development phase
260 participants
Enrollment target

Study Summary

The study is designed to determine if the administration of multi-drug adjuvant chemotherapy for patients with primary non-metastatic osteogenic sarcoma, both prior to and after the definitive surgical procedure for their primary tumor is superior as a treatment strategy to the current approach of giving drugs only after the definitive surgical procedure has been performed. An effort will be made as well to determine if the administration of pre-definitive surgery, chemotherapy leads to an increase in the proportion of the patients suitable for a limb salvage primary surgical procedure.

Interventions

  • DRUG pre-surgical chemotherapy

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 1987-05
Est. Completion 2000-12
Phase Phase 3

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00001217

The ClinicalTrials.gov registry entry for NCT00001217 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which pre-surgical chemotherapy is the first listed.

NCT00001217 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00001217 about?

NCT00001217 is a clinical study titled "Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study". The study is designed to determine if the administration of multi-drug adjuvant chemotherapy for patients with primary non-metastatic osteogenic sarcoma, both prior to and after the definitive surgical procedure for their primary tumor is superior as a treatment strategy to the current approach of g...

What is the current status of trial NCT00001217?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 1987-05. Estimated completion is 2000-12.

What interventions are being tested in trial NCT00001217?

The interventions under investigation include: pre-surgical chemotherapy (DRUG).

Who is sponsoring clinical trial NCT00001217?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.